Last reviewed · How we verify
Simbrinza 0.2%-1% Ophthalmic Suspension
Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production.
Simbrinza combines a beta-adrenergic antagonist and a carbonic anhydrase inhibitor to reduce intraocular pressure by decreasing aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Simbrinza 0.2%-1% Ophthalmic Suspension |
|---|---|
| Sponsor | Prairie Eye Center |
| Drug class | Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist |
| Target | Carbonic anhydrase II; alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Simbrinza contains brinzolamide (carbonic anhydrase inhibitor) and brimonidine (alpha-2 adrenergic agonist). Brinzolamide inhibits carbonic anhydrase in the ciliary body, reducing aqueous humor secretion. Brimonidine stimulates alpha-2 adrenergic receptors to further decrease aqueous humor production and increase uveoscleral outflow. Together, these mechanisms lower intraocular pressure in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Blurred vision
- Conjunctival hyperemia
- Ocular irritation
- Taste perversion
- Allergic conjunctivitis
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections (NA)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) (PHASE4)
- 24-hr Intraocular Pressure Control With SIMBRINZA ® (PHASE4)
- Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification (NA)
- Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simbrinza 0.2%-1% Ophthalmic Suspension CI brief — competitive landscape report
- Simbrinza 0.2%-1% Ophthalmic Suspension updates RSS · CI watch RSS
- Prairie Eye Center portfolio CI